Introduction {#s1}
============

Infectious diseases caused by pathogenic organisms such as viruses, bacteria, fungi, and parasites are still responsible for the majority of hospitalization and death worldwide. Although considerable achievement has been made by using antibiotic agents varying from small-molecule drugs, peptides/proteins, to nucleic acids, there remain great challenges in effective treatment of infectious diseases ([@B100]; [@B37]; [@B73]). In addition to severe side effects of currently existing antiviral and antibacterial agents due to their systemic exposure, the rapid emergence of drug resistance is a serious global health problem ([@B12]; [@B102]). Moreover, new viruses and bacteria are constantly emerging by evolution or other biological events, leading to a continuing challenge in control and prevention of infectious diseases. Consequently, in addition to discovering new antiviral agents and antibiotics for infection control, creative strategies need to be developed to maximize efficacy of currently available drugs ([@B163]; [@B38]). Indeed, as one of the most straightforward and cost-effective strategies, vaccination has greatly reduced the morbidity and mortality resulting from infectious diseases. Unfortunately, vaccines remain unavailable for many infectious diseases ([@B58]), such as *Chlamydia* and *M. tuberculosis* infections. In other cases, there are still safety concerns for the use of vaccines based on inactivated or attenuated live pathogens, while recently developed subunit vaccines usually show poor immunogenicity. Accordingly, innovative technologies are desperately needed for vaccine development ([@B115]).

Nanotechnology has been emerging as a new strategy to circumvent multiple disadvantages of antiviral drugs and antibiotics as well as to potentiate their therapeutic benefits ([@B56]; [@B103]; [@B137]). In this aspect, a diverse array of nanoparticles have been examined to improve the efficacy and decrease side effects of various therapeutics in the treatment of infectious diseases ([@B166]), by increasing drug solubility/stability, prolonging circulation time, overcoming biological barriers, enhancing bioavailability, targeting infection sites, and modulating drug release profiles in response to biochemical signals relevant to pathological changes ([@B174]; [@B49]; [@B179]). Furthermore, increasing evidence has demonstrated that nanoparticle-based strategies hold great potential to reduce resistance development or even reverse acquired resistance ([@B77]), by promoting intracellular uptake, changing the delivery route in subcellular organelles, modulating drug--pathogen interactions, and/or conferring anti-biofilm effect ([@B2]; [@B44]; [@B136]; [@B57]).

In addition, numerous studies have substantiated that nanoparticles are promising for amplifying the activity of antigens and adjuvants by promoting humoral and cellular immunity ([@B9]; [@B148]; [@B146]). Due to their unique biophysicochemical properties, nanoparticles can protect antigens from proteolytic degradation and achieve targeted delivery in immunity-related lymphoid tissues, antigen-presenting cells, and subcellular compartments of interest ([@B86]; [@B118]; [@B4]). Based on these features, nanoparticles allow lower doses of subunit vaccines to afford desirable immune responses, and notably inhibit the nonspecific immune activation resulting from systemic delivery of soluble antigens ([@B167]; [@B17]; [@B94]). Also, antigens can be site-specifically delivered to mucosal surfaces, thereby generating expected mucosal immunity for protection against pathogens transmitted *via* the mucosa ([@B20]; [@B112]). Furthermore, nanoparticle-mediated intracellular delivery of exogenous antigens is able to notably increase cross-presentation, which is highly preferred for protective and therapeutic vaccines ([@B138]).

Recently, nanotechnology has been combined with biomimetic strategies to create bioinspired nanoparticles with optimized surface biophysicochemical properties for drug delivery and vaccine development ([@B6]; [@B93]; [@B116]; [@B177]; [@B180]). These biomimetic nanoparticles possess multiple advantages, such as the diversity, tailorability, and reproducibility of synthetic nanomaterials as well as the functionality, complexity, and biocompatibility of biological materials ([@B170]; [@B101]). Due to their intrinsic activity, nature-inspired nanoparticles themselves can function as effective nanotherapies or nanovaccines against infectious diseases. Alternatively, they may serve as advanced nanocarriers for site-specific delivery of therapeutics or vaccines. Herein, we review recent progress in biomimetic and bioengineered nanotherapies for the management of infectious diseases. Different nanoparticles based on viruses, bacteria, and mammalian cells are first introduced. We then highlight applications of different biomimetic nanoparticles in anti-infective therapy. Also, nanovaccines engineered from bioinspired strategies are described, with emphasis on the prevention or therapy of infectious diseases. Finally, major issues regarding the translation and clinical applications of these bioinspired nanotherapies are discussed.

Different Biomimetic Nanoparticles Developed for the Treatment of Infectious Diseases {#s2}
=====================================================================================

Over the past decades, nanoparticles derived from viruses, bacteria, and mammalian cells have been developed for delivery of diagnostic or therapeutic agents for the management of infectious diseases. Due to their special properties, these biomimetic nanovehicles can effectively transport the loaded cargo molecules to diseased sites without inducing immune responses. Herein, we briefly introduce different types of biomimetic and bioinspired nanoparticles used for therapy of infectious diseases.

Virus-Based Nanoparticles {#s2_1}
-------------------------

Viruses can efficiently bind to host cells by specific interactions between virion proteins and lipids, membrane proteins, or carbohydrate moieties on the cell surface. This attachment is generally followed by virus entry in host cells *via* endocytosis/pinocytosis or fusion/penetration. Moreover, viruses have developed various strategies to evade the host immune system. Accordingly, different approaches have been established to construct biomimetic nanoparticles, taking advantage of the unique capabilities of viruses ([**Figure 1**](#f1){ref-type="fig"} and [**Table 1**](#T1){ref-type="table"}).

![Schematic illustration of virus-mimetic nanoparticles. **(A)** Virosomes. **(B)** Virus-like particles (VLPs). **(C)** Self-assembling nanoparticles displaying antigens on their surface. **(D)** Fully synthetic nanoparticles mimicking viruses.](fphar-10-00751-g001){#f1}

###### 

Different biomimetic nanoparticles discussed in this review.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Types of biomimetic nanoparticles                      Definition                                                                                                                                                                                                        Applications                                                                                                                                                                               References                                                                      
  ------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------- -------------------------------------------------------------------------------------
  Virus-based nanoparticles                              Virosomes                                                                                                                                                                                                         Spherical vesicles consisting of phospholipid bilayers with incorporated virus-derived proteins.                                                                                           Vaccination, drug/gene delivery                                                 ([@B88]; [@B106]; [@B15]; [@B16]; [@B105]; [@B80]; [@B85])

  Virus-like particles                                   Assemblies of viral capsids or envelope proteins derived from viruses.                                                                                                                                            Vaccines, drug delivery                                                                                                                                                                    ([@B138]; [@B139]; [@B89]; [@B31]; [@B66]; [@B131]; [@B60])                     

  Self-assembling\                                       Nanoparticles self-assembled by natural proteins with displayed viral glycoproteins or other antigens.                                                                                                            Vaccines                                                                                                                                                                                   ([@B71]; [@B46]; [@B32]; [@B123])                                               
  nanoparticles                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Fully synthetic nanoparticles                          Fully synthesized nanoparticles that can mimic functions of viruses.                                                                                                                                              Drug delivery, gene therapy                                                                                                                                                                ([@B97]; [@B123])                                                               

  Nanoparticles derived from bacteria or fungi           Nanoparticles derived from components of the bacterial/fungal membrane                                                                                                                                            Nanoparticles directly formulated from the components of the bacterial or fungal membrane or nanoparticles based on a chemically modified component of the bacterial or fungal membrane.   Targeted drug delivery                                                          ([@B149])

  Outer membrane vesicles                                Also referred to as bacterial extracellular vesicles, which are spherical bilayered structures enriched with bioactive molecules, such as proteins and nucleic acids.                                             Biomimetic therapies, targeted drug delivery                                                                                                                                               ([@B160]; [@B3]; [@B87]; [@B91]; [@B133]; [@B157]; [@B159]; [@B172]; [@B158])   

  Nanoparticles coated with bacterial membrane           Synthetic nanoparticles decorated with the bacterial-derived membrane                                                                                                                                             Antibacterial nanotherapies, vaccines                                                                                                                                                      ([@B51])                                                                        

  Nanoparticles mimicking mammalian cells                Cell membrane-coated nanoparticles                                                                                                                                                                                Synthetic nanoparticles coated with different cell membranes derived from mammalian cells, such as red blood cells, platelets, leukocytes, dendritic cells, and stem cells.                Biodetoxification, drug/gene delivery, vaccines                                 ([@B65]; [@B117]; [@B62]; [@B42]; [@B64]; [@B122]; [@B25]; [@B41]; [@B108]; [@B26])

  Nanoparticles decorated with functional biomolecules   Nanoparticles decorated with plasma membrane-derived proteins, simultaneously coated with multiple biomolecules, or coated with biomimetic molecules to mimic the natural process of different mammalian cells.   Targeted drug/gene delivery                                                                                                                                                                ([@B129]; [@B130]; [@B107])                                                     

  Shedding microvesicles                                 Vesicles formed by the outward budding of the cytoplasmic membrane.                                                                                                                                               Targeted drug delivery                                                                                                                                                                     ([@B29]; [@B45]; [@B156])                                                       

  Exosomes                                               Extracellular vesicles originated from exocytosis of multivesicular bodies by eukaryotic cells.                                                                                                                   Nanotherapies, targeted drug/gene delivery                                                                                                                                                 ([@B147]; [@B114]; [@B121]; [@B47]; [@B48]; [@B67]; [@B173])                    

  Other biomimetic nanoparticles                         High-density lipoproteins                                                                                                                                                                                         Lipid-protein nanoparticles with a mean diameter of 8--10 nm, carrying a large number of different proteins such as apolipoproteins.                                                       Biomimetic nanotherapies, drug delivery, biodetoxification                      ([@B164]; [@B18]; [@B95]; [@B124])
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In the first strategy, virus-derived proteins are incorporated in unilamellar liposomes that are spherical vesicles consisting of phospholipid bilayers, resulting in the formation of virosomes with size ranging from 20 to 200 nm ([@B5]; [@B69]) ([**Figure 1A**](#f1){ref-type="fig"}). Generally, envelope glycoproteins derived from influenza virus, such as hemagglutinin (HA) and neuraminidase (NA), are reconstituted with liposomes to prepare virosomes for vaccination or delivery of different therapeutics ([@B33]). Also, other enveloped viruses, such as hemagglutinating virus of Japan (HVJ), respiratory syncytial virus (RSV), and vesicular stomatitis virus (VSV), can be used to generate virosomes ([@B142]; [@B88]; [@B106]; [@B105]; [@B80]). In other cases, human hepatitis B virus-derived nanoparticles were fused with liposomes, giving rise to virosome-like particles ([@B70]). In addition to affording structural stability to virosomes, the introduced lipoproteins are responsible for disease targeting, cellular uptake, and endolysosomal escape after internalization ([@B36]). Virosomes have multiple advantages, such as ease of production and modification, biodegradability, biocompatibility, promoted fusion activity in the endolysosomes, and capabilities of delivering various drugs and protecting biologics from degradation. Nevertheless, their broad applications remain limited, largely due to the potential risk of immunogenicity. This issue can be partly addressed by modification of virosomes with polyethylene glycol (PEG) and targeting moieties ([@B74]; [@B132]). In this aspect, different ligands and antibodies are incorporated into virosomes to reduce off-target effects ([@B74]; [@B85]).

In the second approach, virus-like particles (VLPs) are assembled by viral capsids or envelope proteins derived from viruses, with the advantages of precisely defined structures, capacity of packaging different drugs, and displaying functional moieties on their surfaces ([**Figure 1B**](#f1){ref-type="fig"}). Of note, VLPs can also be formed by synthetic viral capsids ([@B99]). The pristine VLPs can be further modified to afford additional functions by tailoring VLP proteins *via* genetic and chemical engineering ([@B139]; [@B60]). For instance, hydrophilic polymers are conjugated on VLPs to increase stability, prolong circulation time, reduce nonspecific absorption, or attenuate immune responses ([@B144]; [@B96]). On the other hand, to overcome the disadvantages of the natural tropism of VLPs, different chemical functionalization methods have been developed to conjugate various targeting ligands on VLPs for site-specific drug delivery ([@B139]). Since the antigenicity of VLPs is comparable to their parent viruses, they are initially synthesized for vaccination. Nevertheless, VLPs can be engineered to deliver various drugs varying from small-molecule drugs, peptides, proteins, to nucleic acids, in which therapeutic molecules are packaged by either non-covalent interaction-mediated physical loading or chemical conjugation ([@B165]; [@B78]; [@B131]).

In a new strategy, self-assembling nanoparticles are obtained by displaying viral glycoproteins with natural proteins that have the ability to form nanoparticles by self-assembly ([**Figure 1C**](#f1){ref-type="fig"}). An elegant example was shown in a study by Nabel and colleagues ([@B71]), in which influenza HA was genetically fused to ferritin, and the obtained fusion glycoprotein can spontaneously assemble into nanoparticles, thereby exposing eight HA trimers on their surface ([**Figure 2A and B**](#f2){ref-type="fig"}). Most recently, a computational protein design method was used to develop a self-assembling nanoparticle bearing antigen from RSV ([**Figure 1D**](#f1){ref-type="fig"}) ([@B97]). In this case, a rationally designed, self-assembling protein nanoparticle serves as a scaffold for multivalent presentation of a prefusion-stabilized variant of the F glycoprotein trimer of RSV, with a repetitive array and controllable density ([**Figure 2C--E**](#f2){ref-type="fig"}). This *in silico* designed and fully synthetic nanoparticle exhibits optimized stability, immunogenicity, and adjuvanticity ([@B97]).

![Molecular design and characterization of virus-mimicking self-assembling nanoparticles. **(A, B)** Construction of hemagglutinin (HA)-ferritin fusion protein-assembled nanoparticles displaying influenza virus HA. **(A)** A subunit of *H. pylori* non-haem ferritin \[protein data bank (PDB: 3bve)\] (left). The NH~2~- and COOH-termini are labeled as N and C, respectively. Three subunits surrounding a threefold axis are shown (middle) and Asp 5 is colored in red. An assembled ferritin nanoparticle and an HA trimer (PDB: 3sm5) (viewed from membrane proximal end) (right). A triangle connecting the Asp 5 residues at the threefold axis is shown in red. The same triangle is drawn on the HA trimer (right). A schematic representation of the HA-ferritin fusion protein is shown (bottom). **(B)** Negatively stained transmission electron microscopy (TEM) images of HA nanoparticles. **(C--E)** Design, *in vitro* assembly, and structural characterization of DS-Cav1-I53-50. **(C)** Schematic representation of the computational docking protocol used to identify nanoparticle components suitable for fusion to DS-Cav1. The C termini of the foldon and N termini of the nanoparticle trimer are shown as red and blue spheres, respectively, and the exterior and interior surfaces of the nanoparticle are depicted. **(D)** Structural model of DS-Cav1-I53-50 and schematic of the *in vitro* assembly process. Each nanoparticle comprises 20 trimeric and 12 pentameric building blocks for a total of 60 copies of each subunit. **(E)** Negatively stained TEM image of I53-50 and DS-Cav1-I53-50 nanoparticles. The two images on the right are averages of negatively stained particles. Images **(A)** and **(B)** are reprinted with permission from [@B71]. © (2013) Macmillan Publishers Limited. Images **(C)--(E)** are reprinted with permission from [@B97]. © (2019) Elsevier Inc.](fphar-10-00751-g002){#f2}

Finally, virus-mimetic nanoparticles have been developed by different biomimetic methods. Bae et al. synthesized a virus-mimetic nanogel that consists of a hydrophobic polymer core and a capsid-like outer shell ([@B82]). The obtained nanovehicle can significantly mimic viral properties, since it is able to efficiently infect cells, effectively kill cells, and migrate to neighboring cells. A virus-mimetic nanocapsule was constructed by self-assembly of iron oxide nanoparticles and a one-component functional protein lactoferrin, which can encapsulate both hydrophilic and hydrophobic drugs ([@B40]). By mimicking different modular components of viruses, a multicomponent virus-mimetic nanoparticle was prepared, in which membrane-disrupting peptides, nucleic acid binding components, a protective layer, together with an outer targeting ligand were incorporated for programmed gene delivery ([@B141]). Recently, a polymer-templated protein nanoball with well-controlled displaying of HA1 on its surface was prepared as a novel influenza virus-mimetic nanoparticle ([@B81]). Using silica-based nanoparticles, nonviral nanoparticles mimicking virus surface topography were successfully synthesized by Yu and coworkers, which showed enhanced cellular delivery of small interfering RNA (siRNA) ([@B113]).

Nanoparticles Derived From Bacterial or Fungal Pathogens {#s2_2}
--------------------------------------------------------

Since recognition interactions among biomolecules on the bacterial/fungal membrane and host cells is the first step toward their adhesion and entry into target cells ([@B120]), different components of the bacterial/fungal membrane have been used for preparation of nanoparticles to partly recapitulate their natural features or to realize targeted treatment of bacterial or fungal infection ([**Table 1**](#T1){ref-type="table"}). For instance, chitosan, an important component of the vegetative cell wall of *C. neoformans* ([@B11]), was utilized to formulate nanoparticles, resulting in a *C. neoformans*-targeted drug delivery system ([@B149]).

Another type of bacterial-derived nanoparticles are bacterial extracellular vesicles, also referred to as outer membrane vesicles (OMVs), which are spherical bilayered structures (10--30 nm in diameter) enriched with bioactive molecules, such as proteins and nucleic acids ([@B75]). OMVs have been investigated as therapies or biomimetic nanovehicles for targeted drug delivery ([@B160]; [@B87]; [@B91]; [@B133]; [@B159]; [@B172]; [@B158]). Based on the similar consideration, microbiota-derived extracellular vesicles were examined for therapeutic applications ([@B3]), in view of the fact that dysbiosis of gut microbiota is closely related to the pathogenesis of an astounding array of diseases ([@B152]). Moreover, these vesicles contain numerous types of compounds capable of affecting diverse pathways in the host. Besides, OMVs can be used to prepare functional nanoparticles with coated bacterial membrane for the development of effective antibacterial nanotherapies or nanovaccines ([@B50]). Generally, OMVs are produced by membrane blebbing or membrane budding, which are then isolated for different applications ([@B22]). To overcome limitations of OMVs based on this natural process, such as poor batch-to-batch quality control and barriers to scalability, a facile method was established by Wang and coworkers ([@B157]). In this approach, bacterial membrane is physically disrupted by nitrogen cavitation. The cellular membrane thus obtained can spontaneously form nanoscale vesicles. It should be noted that, in addition to bacteria, extracellular vesicles may be produced from fungi ([@B22]).

Nanoparticles Mimicking Mammalian Cells {#s2_3}
---------------------------------------

Recently, different strategies have been developed to engineer nanoparticles mimicking the diverse functions of various types of mammalian cells, including red blood cells (RBCs), platelets, leukocytes, dendritic cells, and stem cells ([**Table 1**](#T1){ref-type="table"}) ([@B117]; [@B62]; [@B64]; [@B27]; [@B28]; [@B176]). Initially, the erythrocyte membrane was coated on poly(lactic-co-glycolic acid) (PLGA) nanoparticles to extend their *in vivo* circulation time ([**Figure 3A and B**](#f3){ref-type="fig"}) ([@B65]). Since then, cell membranes derived from different cells have been examined for surface functionalization of a variety of nanomaterials, including nanoparticles based on synthetic or natural polymers, silica, gold, and iron oxide, as well as nanogels, quantum dots, upconversion nanoparticles, and metal organic frameworks ([@B42]; [@B41]). To prepare cell membrane-coated nanoparticles, different coating technologies can be used. In most studies, the coextrusion method is adopted, in which nanoparticulate cores and membrane vesicles of interest are extruded through a porous membrane with specific pore size. Alternatively, microfluidic systems can be used to cloak nanoparticles with cellular membranes ([@B122]; [@B108]).

![Engineering of cell-mimetic nanoparticles. **(A)** Schematic illustration of the preparation process of the red blood cell (RBC) membrane-coated poly(lactic-co-glycolic acid) (PLGA) nanoparticles. **(B)** Representative TEM images of uranyl acetate-stained RBC membrane-coated PLGA nanoparticles (NPs). **(C--F)** Synthesis, formulation, and characterization of leukosomes. **(C)** Extraction of proteolipid materials from murine J774 macrophages. **(D)** Protein enrichment of the phospholipid film. **(E)** Vesicular formulation of leukosomes. **(F)** Cryo-TEM analysis of leukosomes. NPs, nanoparticles; DPPC, 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine; DSPC, 1,2-distearoyl-sn-glycero-3-phosphocholine; DOPC, 1, 2-dioleoyl-sn-glycero-3-phosphocholine; CHOL, cholesterol. Images **(A)** and **(B)** are reprinted with permission from [@B65]. © (2011) National Academy of Sciences. Images **(C)--(F)** are reprinted with permission from [@B107]. © (2016) Macmillan Publishers Limited.](fphar-10-00751-g003){#f3}

Nevertheless, scale-up preparation and translation studies of the cell membrane-coated nanoparticles remain limited, largely due to the complicated synthetic routes and purification procedures as well as relatively poor reproducibility. To overcome these limitations, Tasciotti's group developed a method that can leverage the advantages of bottom-up and top-down strategies ([**Figure 3C--F**](#f3){ref-type="fig"}) ([@B107]; [@B108]). In this scenario, proteins derived from the leukocyte plasma membrane were incorporated into lipid nanoparticles, resulting in leukosomes capable of encapsulating drugs with variable solubility and site-specifically delivering the cargo molecules to the inflamed endothelium.

In addition, nanoparticles have been decorated with functional molecules to achieve specific biological features. For example, leukocyte-like avid adhesion was achieved by nanoparticles coated with ligands that mediate two leukocyte adhesion pathways ([@B129]). In this case, polymersomes were functionalized with sialyl Lewis X and an intercellular adhesion molecule (ICAM)-1 antibody, resulting in avid and selective binding to surfaces coated with P-selectin and ICAM-1 (both are adhesion molecules involved in inflammatory diseases), even under flow. On the other hand, macrophage-mediated clearance of intravenously delivered nanoparticles can be significantly delayed by coating with self peptides that are computationally designed from a human membrane protein CD47 ([@B130]).

Also, mammalian cell-derived vesicles (CDVs) have been extensively explored for their intrinsic activities and diversity in therapeutic loading capacity ([@B45]; [@B156]). Shedding microvesicles and exosomes are two major types of CDVs, which can be generated by almost all cell types in physiological and pathological conditions. Shedding microvesicles (with diameter of 10--1,000 nm) are formed by the outward budding of the cytoplasmic membrane, while exosomes (30--200 nm) originate from exocytosis of multivesicular bodies ([@B29]). Because CDVs are important mediators responsible for intercellular communications and the horizontal transfer of membrane/cargo molecules (such as cytokines, proteins, and nucleic acids), they have been investigated as modulators, regulators, diagnostic probes, and therapeutic targets ([@B114]; [@B121]; [@B67]). Taking advantage of their innate capacities to escape immune clearance, recognize target cells, and overcome biological barriers, CDVs are also used as smart drug delivery carriers, either in their native forms or after re-engineering by genetic or chemical modification ([@B55]; [@B154]; [@B8]).

Another type of CDVs can be directly formulated by mammalian cells. As an elegant example, Wang's group has established a nitrogen cavitation technique to efficiently generate cell membrane nanovesicles ([@B47]; [@B48]; [@B173]). In this approach, mechanical forces produced by nitrogen cavitation can rapidly disrupt cell membranes of activated neutrophils, and subsequent assembly of the broken membrane gives rise to nanoscale vesicles, with thickness and protein profiles similar to those of the cell membrane of parent cells. Compared to other methods used for the preparation of CDVs, this technique shows high yield, good reproducibility, and desirable scale-up capacity.

Other Biomimetic Nanoplatforms {#s2_4}
------------------------------

Besides the above-mentioned nanoparticles, other biomimetic nanoplatforms, such as hepatitis B virus envelope L particles and lipid nanoparticles ([**Table 1**](#T1){ref-type="table"}), have been examined as functional delivery carriers for treatment of diverse diseases ([@B168]; [@B85]). Among them, high-density lipoproteins (HDLs) are probably the most extensively studied nanovehicles for drug delivery ([@B95]; [@B124]). HDLs are lipid-protein nanoparticles with a mean diameter of 8--10 nm, carrying a large number of different proteins such as apolipoproteins. Whereas HDLs are well known for their role in cholesterol transport and lipid metabolism, increasing evidence has demonstrated their potential for therapy of sepsis ([@B164]). In addition, both native HDLs and reconstituted HDLs (rHDLs) can function as effective nanoplatforms for targeted drug delivery in cardiovascular and hepatic diseases ([@B111]; [@B104]; [@B95]).

Applications of Bioinspired Nanoparticles in Antiviral Therapy {#s3}
==============================================================

It has been demonstrated that antiviral drugs can be loaded in liposomes, micelles, dendrimers, or polymer/lipid nanoparticles to increase their stability, prolong half-life, and realize targeted delivery to specific tissues (such as lymphatic tissues) or cells infected by viruses ([@B103]; [@B137]). In this context, albumin nanoparticles loaded with an antiretroviral drug efavirenz were prepared for potential treatment of human immunodeficiency virus (HIV) infection ([@B68]), resulting in improved efavirenz delivery to several organs. Also, siRNA nanosomes were formulated by packaging lipid nanoparticles with multiple siRNAs that target the highly conserved 5′-untranslated region of the hepatitis C virus (HCV) genome. In mice, systemic treatment with siRNA nanosomes significantly inhibited HCV replication ([@B24]). In addition, intravaginal delivery of siRNA-loaded PLGA nanoparticles effectively prevented genital herpes simplex virus (HSV)-2 infections in mice ([@B143]). By using pathologically responsive nanocarriers, in combination with specific targeting moieties, efficacy of antiviral nanotherapies may be further improved. Studies by Bronshtein et al. showed a biomimetic strategy capable of effectively targeting HIV-infected cells ([@B21]). In this approach, vesicles were prepared from cells expressing a chemokine receptor CCR5, which is the human receptor for envelope glycoprotein GP120 found on HIV-infected cells. The specific targeting capability of CCR5-conjugated cell-derived vesicles was substantiated by *in vitro* experiments in GP120-expressing HIV model cells.

On the other hand, Davis' group developed virus-like glycodendrinanoparticles bearing approximately 1,620 glycans ([**Figure 4A**](#f4){ref-type="fig"}) ([@B126]), considering the pivotal role of ligand polyvalency in mediating host--pathogen interactions. The constructed nanoparticles, with mean diameter of 32 nm, can mimic viral pathogens with respect to both size and glycosylated surface. In an Ebola viral infection model in mammalian T lymphocytes, these biomimetic glycodendriprotein nanoparticles showed exciting antiviral activity, and they effectively prevented mammalian cell infection by competitively blocking the dendritic cell-specific ICAM-3-grabbing nonintegrin receptor. Based on the similar principle, antiviral nanoparticles (defined as MUS : OT-NPs) were designed and constructed by coating Au nanoparticles with long and flexible linkers mimicking heparin sulfate proteoglycans (HSPG) that are highly conserved receptors for viral attachment ([**Figure 4B**](#f4){ref-type="fig"}) ([@B23]). *In vitro* experiments demonstrated that thus developed nanoparticles exhibited desirable virucidal activity in HSPG-dependent viruses, including HSV-1, HSV-2, human papillomavirus (HPV), respiratory syncytial virus (RSV), lentivirus, and dengue virus. Importantly, these broad-spectrum antiviral nanoparticles are active in a mouse model of RSV infection.

![Design of biomimetic antiviral nanotherapies. **(A)** Nested symmetrical assembly of virus-like glycodendrinanoparticles using a tag-and-modify strategy. Glycodendrons are created through iterative multivalent assembly and then attached to multiple tags, each in a monomer protein. **(B)** Cartoon of the virucidal activity of broad-spectrum antiviral nanoparticles MUS : OT-NPs compared to MES-NPs. HSPG, heparin sulfate proteoglycans; MES, 3-mercaptoethylsulfonate; MUS, undecanesulfonic acid; OT, 1-octanethiol. Image **(A)** is reprinted with permission from [@B126]. © (2012) Macmillan Publishers Limited. Image **(B)** is reprinted with permission from [@B23]. © (2018) Macmillan Publishers Limited.](fphar-10-00751-g004){#f4}

Biomimetic Nanoparticles for Treatment of Bacterial Infections {#s4}
==============================================================

Treatment of Bacterial Infections by Toxin-Neutralizing Nanoparticles {#s4_1}
---------------------------------------------------------------------

Bacteria and fungi generally produce a variety of microbial toxins, classified as endotoxins and exotoxins that can promote infection and disease pathogenesis by directly damaging the host cell membrane and tissues as well as impairing the immune system ([@B92]). Increasing evidence has demonstrated the effectiveness of injectable nanoparticles for biodetoxification by neutralizing toxins ([@B84]; [@B42]). For example, synthetic nanoparticles based on copolymers of acrylic acid, N-tert-butylacrylamide, N-isopropylacrylamide, and N,N′-methylenebisacrylamide could effectively capture and neutralize the toxicity of a peptide toxin melittin by electrostatic and hydrophobic interactions ([@B61]; [@B171]). By coating monosialotetrahexosylganglioside (GM1), a key host receptor for cholera toxin, on the surface of PLGA nanoparticles, an effective toxin-neutralizing nanoplatform was obtained, which can selectively neutralize the effects of cholera toxin on epithelial cells ([@B35]). Moreover, the GM1-coated nanoparticle decoys effectively attenuated intestinal secretory responses of live *V. cholerae* in a murine infection model. For these nanoparticles, however, their affinity to different types of toxins and the antivirulence activity remain to be enhanced. In addition, *in vivo* safety of the toxin-affinity nanoparticles derived from acryl compounds should be carefully examined, since they are nondegradable under physiological conditions.

To address these limitations, lipid-based cell membrane-mimicking nanostructures have been applied as novel decoys to efficiently neutralize toxins ([@B19]). Given the fact that the plasmalemma is mainly composed of glycerophospholipids, sphingolipids, and cholesterol, Henry et al. developed liposomes composed of sphingomyelin and high concentrations of cholesterol, which could efficiently absorb membrane-damaging toxins and α-hemolysin ([@B59]). Furthermore, these artificial liposomes are able to efficiently sequester a broad spectrum of toxins released by a variety of staphylococcal and streptococcal pathogens. Intravenous administration of these exotoxin-absorbing liposomes significantly rescued mice from septicemia caused by *S. aureus* and *S. pneumonia*. Also, liposomes protected mice against invasive pneumonia after intranasal infection with *S. pneumoniae* serotype 2 (strain D39). These beneficial effects were demonstrated to be contributed by sequestration of secreted bacterial toxins, which protected host cells from the lysis and uncontrolled inflammatory responses. Of note, *in vivo* efficacy of liposomes can be further enhanced by combination with antibiotic treatment, as exemplified by using a model antibiotic vancomycin.

Due to the presence of toxin receptors, natural lipoproteins are able to spontaneously interact with different membrane-active toxins such as hemolysins ([@B10]; [@B161]; [@B134]; [@B76]), thereby abrogating their lytic effects. *In vivo* studies in humans demonstrated that HDLs can attenuate inflammatory and coagulation responses after an endotoxin challenge ([@B14]). To further enhance toxin affinity, ganglioside GM1 was incorporated into rHDLs. Thus, engineered rHDLs showed notably increased binding affinity to cholera toxin, and they effectively reduced toxin attachment to epithelial cells *in vitro* ([@B18]).

Recent studies by Zhang's group demonstrated that cell membrane-functionalized nanostructures may serve as promising toxin-neutralizing decoys ([@B42]). Nanosponges based on RBC membrane-coated PLGA nanoparticles effectively neutralized different pore-forming toxins, such as melittin, α-hemolysin, listeriolysin O, and streptolysin O, and therefore, they could significantly inhibit toxin-induced hemolysis ([**Figure 5**](#f5){ref-type="fig"}) ([@B62]; [@B39]; [@B178]; [@B25]). Also, the biomimetic nanosponges exhibited desirable neutralization capacity for the whole secreted proteins of methicillin-resistant *S. aureus* (MRSA) ([@B26]). Furthermore, the antivirulence efficacy of these nanosponges was demonstrated by *in vivo* studies in different mouse models. Through the similar strategy, macrophage-like nanoparticles were developed by wrapping PLGA cores with the macrophage cell membrane ([@B151]). The obtained macrophage-mimetic nanoparticles showed effective binding and neutralization of endotoxins. In a mouse model of *E. coli*-induced bacteremia, treatment with these biomimetic nanoparticles afforded a significant advantage for sepsis control. In addition to lipopolysaccharide (LPS) neutralization, simultaneous sequestration of proinflammatory cytokines was considered to be responsible for the therapeutic benefits of these macrophage-mimicking nanoparticles.

![Schematic, characterization, and *in vivo* evaluation of a pore-forming toxin-absorbing biomimetic nanosponge. **(A)** Schematic of a toxin nanosponge and the mechanism of neutralizing pore-forming toxins. The nanosponge consists of substrate-supported RBC bilayer membranes into which pore-forming toxins can be incorporated. **(B)** TEM images of nanosponges mixed with α-toxin (scale bar, 80 nm) and the zoomed-in view of a single toxin-absorbed nanosponge (scale bar, 20 nm). **(C--E)** Mice injected with α -toxin/nanosponges. No skin lesion occurred **(C)**. No abnormality was observed in the epidermis **(D)**. Normal muscle structure was observed **(E)**. Images are reprinted with permission from ([@B62]). © (2013) Macmillan Publishers Limited.](fphar-10-00751-g005){#f5}

Treatment of Bacterial Infections by Drug-Loaded Biomimetic Nanoparticles {#s4_2}
-------------------------------------------------------------------------

The combination of nanotechnology with antibiotics represents a very promising strategy for antibacterial therapy. During the past decades, different antibiotics have been loaded in nanoparticles with varied biophysicochemical properties to achieve site-specific and/or intracellular delivery of therapeutics, in particular for combating multi-drug resistant bacteria ([@B166]; [@B174]; [@B49]). In these antibacterial nanotherapies, antibiotics of diverse structures can be physically absorbed on, entrapped in, or covalently conjugated with metal, inorganic, and polymer nanoparticles as well as nanogels, nanoemulsions, liposomes, and hybrid nanovehicles ([@B119]; [@B79]; [@B136]). Also, different antibacterial agents can be co-delivered through specific nanocarriers to achieve synergistic effects. In addition to diffusion, release of antibacterial cargoes may be triggered by pathological signals at infection sites, such as pH, reactive oxygen species, and bacterial toxins or lipases ([@B79]; [@B110]). Compared to free antibacterial agents, drug-loaded antibiotic nanoparticles displayed enhanced drug stability, targeted delivery, prolonged retention, sustained or responsive release, and enhanced penetrating capability. Due to these multiple functions, antibacterial nanotherapies can effectively overcome decreased uptake and increased efflux of drugs by bacteria, considerably prevent biofilm formation, and notably combat intracellular bacteria.

Despite extensive studies in this field, there are still tremendous challenges in precisely targeting bacteria or infected cells and delivering antibiotics to subcellular compartments with bacteria. Recent studies suggested that biomimetic nanoparticles are effective vehicles for targeted delivery of antibacterial agents. A study by Sun et al. showed that exosomes enhanced delivery of curcumin, a hydrophobic anti-inflammatory drug to activated monocytes *in vivo* ([@B147]). In mouse models of LPS-induced septic shock and LPS-induced brain inflammation, curcumin-loaded exosomes exhibited more significant protective effects compared to free drug ([@B147]; [@B181]). Also, exosomes effectively delivered exogenous siRNA to monocytes and lymphocytes ([@B150]). Similarly, an exogenous miRNA-155 mimic was successfully delivered to macrophages by exosomes ([@B109]), thereby significantly inhibiting LPS-induced inflammation. Besides exosomes, nanovesicles derived from neutrophil-like cells (i.e., HL-60 cells) were examined for targeted drug delivery. In a mouse model of LPS-induced acute lung inflammation, treatment with HL-60 cell-derived nanovesicles loaded with an anti-inflammatory agent TPCA-1 (an NF-κB inhibitor) significantly inhibited neutrophil infiltration and expression of inflammatory cytokines, by targeting inflamed lung vasculature ([@B47]). In another study by the same group, intravenous administration of piceatannol-loaded nanovesicles based on HL-60 cells dramatically reduced local and systemic inflammation in LPS-induced mouse models of acute lung injury and sepsis, respectively ([@B48]).

As well documented, bacteria and other microorganisms can stimulate platelet activation, and the activated platelets may directly bind and capture bacteria ([@B43]; [@B135]). This inherent bacterial adherence capacity of platelets was exploited for targeted delivery of an antibiotic agent vancomycin by using platelet membrane-cloaked PLGA nanoparticles (PNPs) ([@B64]). Preferential binding of a strain of MRSA252 by PNPs was demonstrated by *in vitro* experiments. Furthermore, in a mouse model of systemic MRSA252 infection, vancomycin-loaded PNPs exhibited significantly better antimicrobial efficacy compared to free drug. In another case, an RBC membrane-coated, redox-responsive nanogel (RBC-nanogel) was examined as a smart delivery nanoplatform ([@B178]). Using vancomycin as a model drug, *in vitro* responsive release was confirmed in reducing environment. Further, the intracellular antibacterial efficacy of vancomycin-loaded RBC-nanogel was substantiated in an *in vitro* model of MRSA USA300-infected macrophages derived from human THP-1 monocytes. Based on a similar design principle, the same group developed antibiotic-loaded nanoparticles coated with plasma membranes of gastric epithelial cells to obtain targeting nanotherapies for the treatment of *H. pylori* infection ([@B7]). In a mouse model of *H. pylori* infection, the biomimetic nanoparticles containing an antibiotic clarithromycin showed superior therapeutic efficacy compared to free drug and a non-targeting nanoparticle control. Given that host--pathogen adhesion is a common biological event in the pathogenesis of pathogenic infections, this cell membrane-coating nanotherapeutic strategy may serve as a versatile delivery platform to treat numerous infectious diseases.

Vaccines Based on Bioinspired Nanoparticles {#s5}
===========================================

Virosome-Based Nanovaccines {#s5_1}
---------------------------

In addition to delivery of drugs with different structures, virosomes have been extensively studied as a vaccine platform due to their capacity to simultaneously deliver antigens and adjuvants within a single nanoparticle, thereby activating both humoral and cellular immune responses.

RSV may cause infections in the lungs and respiratory tract, leading to severe respiratory diseases in children and the elderly, while currently no effective vaccines are available in the clinic. Stegmann and colleagues prepared lipopeptide P3CSK4-adjuvanted virosomes from RSV envelopes that can induce high virus-neutralizing antibodies after immunization in mice ([@B142]). Moreover, sterilizing immunity to RSV challenge was achieved by these adjuvanted virosomes in mice and cotton rats. Most recently, Lederhofer et al. developed a virosomal RSV vaccine by incorporation of a lipid adjuvant 3-deacyl-phosphorylated hexa-acyl disaccharide (3D-PHAD) in viral membranes containing glycoproteins G and F ([@B80]). *In vivo* immunization experiments in mice revealed effective production of RSV-specific neutralizing antibodies.

Also, intensive studies have been conducted for the development of influenza vaccines based on virosomes, since influenza virus-caused public health threats and economic damages are still main global concerns. A new chimeric influenza virosome derived from A/PR/8/1934 (H1N1) (PR8) and A/X/47 (H3N2) (X47) viruses was found able to provide complete protection against lethal challenge with PR8 and X47 viruses in mice ([@B1]), by inducing high IgG antibody responses and hemagglutination inhibition (HAI) titers even comparable to those generated by the whole inactivated influenza vaccine. To develop influenza vaccines, a conserved human HLA-A2.1 influenza M1~58--66~ peptide was loaded into virosomes prepared from egg-derived influenza A/PR8/34 H1N1 virus ([@B140]). The peptide-loaded virosomes induced specific CD8^+^ T cells in HLA-A2 transgenic mice, and the efficacy was further increased by adjuvanting with CpG. To modulate adaptive immune responses in the respiratory tract, Blom et al. designed influenza-derived virosomes loaded with a model antigen ovalbumin ([@B15]; [@B16]). By presentation with macrophages and dendritic cells after intranasal administration, robust and antigen-specific CD4^+^ T cell proliferation was induced by ovalbumin-containing virosomes, demonstrating their potential for vaccination or immunotherapy of pulmonary diseases such as allergic asthma. In contrast, ovalbumin-loaded liposomes failed to generate a specific T cell activation.

It is worth noting that the efficacy of DNA vaccines can be improved by targeted delivery with virosomes containing influenza virus HA ([@B52]). In view of the success of the previously developed virosomal hepatitis A vaccine (i.e., Epaxal), which showed a real-time protection for at least 5.5 years in children ([@B155]), the currently studied virosomal vaccines deserve further intensive development.

VLP-Based Vaccines {#s5_2}
------------------

Due to their unique structural features and advantages in safe production, short development time, and many available expression systems ([@B169]), VLPs are attractive candidates of prophylactic and therapeutic vaccines ([@B89]). Some VLP-based vaccines, such as hepatitis B and HPV-based VLPs, have been approved for clinical use, and there are still a number of this type of vaccines that are undergoing clinical trials ([@B66]). Besides their inherent immunogenicity, VLPs can be used as effective platforms for presentation of exogenous antigens in highly immunogenic and multivalent forms, thereby affording chimeric vaccines ([@B98]; [@B60]). Additionally, therapeutic vaccines have been developed based on VLPs derived from various viruses by presenting self-antigens to treat chronic inflammatory or infectious diseases ([@B89]; [@B66]).

In addition to vaccines against viral and bacterial infections, hepatitis B-derived VLPs containing the C-terminus and central repeat region of the circumsporozoite protein (CSP) (i.e., RTS,S) have been successfully developed as a malaria vaccine. Of note, the RTS,S-based vaccine is safe, well tolerated, and immunogenic. It can confer partial efficacy in malaria-naive and malaria-experienced adults as well as children ([@B125]). Currently, further studies are undergoing to improve efficacy of this type of anti-malarial vaccines, such as by formulating VLPs containing a much higher proportion of CSP ([@B31]).

Self-Assembling Nanoparticles {#s5_3}
-----------------------------

Recently, self-assembling nanoparticles bearing antigens have been explored as novel vaccines against different viral infections ([@B46]; [@B123]). Studies by Nabel's group demonstrated that nanoparticles self-assembled by ferritin genetically fused with viral HA can elicit broader and more potent immunity compared to traditional influenza vaccines ([**Figure 2A and B**](#f2){ref-type="fig"}) ([@B71]), showing HAI antibody titers \>10-fold higher than those achieved by the commercial vaccine. Furthermore, antibodies induced by HA nanoparticles derived from 1999 NC effectively neutralized H1N1 viruses from 1934 to 2007. Immunization with the HA nanoparticle (1999 NC) vaccine protected ferrets challenged with 2007 Brisbane virus. A similar strategy was employed by Corbett and coworkers to design Group 2 influenza virus HA stem antigens that were also displayed on self-assembling ferritin nanoparticles ([@B32]). In addition to producing broadly neutralizing antibodies, immunization with these Group 2 HA stem antigen-ferritin nanoparticles protected mice against homosubtypic lethal challenges with influenza viruses. Most recently, a computationally designed, fully synthetic nanoparticle displaying 20 DS-Cav1 trimers of RSV was developed ([**Figure 2C--E**](#f2){ref-type="fig"}) ([@B97]), which induced neutralizing antibody responses approximately 10-fold higher than trimeric DS-Cav1 in mice and nonhuman primates.

Vaccines Derived From Other Virus-Mimetic Nanoparticles {#s5_4}
-------------------------------------------------------

Besides the above-mentioned virus-mimicking vaccination approaches, other strategies have been examined for the development of new vaccines. For example, recombinant HA from influenza virus was incorporated into HDL-like nanodisc particles, consisting of lipid bilayers encircled by membrane scaffold proteins ([@B13]). Intranasal vaccination with this HA-loaded nanodisc elicited a strong anti-HA IgA response, conferring protection against challenge with the influenza (H1N1) virus, with efficacy comparable to that of the commercial vaccines Fluzone and FluMist. In a recent study, a polymer-templated protein nanoball was constructed, displaying HA1 on its surface with controlled orientation and density ([@B81]). Vaccination with this virus-mimetic polymer nanoparticle protected mice from H1N1 challenge, in the absence of adjuvant. More importantly, cross-activities against different types of H1N1 influenza viruses were also achieved.

Robinson's group engineered nanoparticles (20--25 nm) by self-assembly of synthetic coiled-coil lipopeptides ([@B53]), on which helper T-cell and B-cell epitopes can be displayed by linking to each lipopeptide chain. In mice and rabbits, the obtained nanoparticles afforded strong humoral immune responses. Based on a similar design principle ([@B127]), an antibody F425-B4e8-bound V3 loop (from GP120 of HIV-1) mimic was coupled to lipopeptide nanoparticles. The obtained nanoparticles could elicit antibodies and block infection by some strains of HIV-1 in rabbits.

Vaccines Derived From Bacterial Extracellular Membrane Vesicles {#s5_5}
---------------------------------------------------------------

Due to their immunogenic properties, self-adjuvant capacity, potential for modification by genetic engineering, cellular uptake ability by antigen-presenting cells, and the capability to present exogenous antigens, bacterial extracellular vesicles have received increasing attention in vaccine development ([@B172]). Since an OMV-based vaccine against serogroup B *N. meningitidis* was successfully used for epidemic control in several countries in 2004 (with vaccination efficacies varying from 83% to 94%) ([@B34]), either natural or bioengineered OMVs have been intensively investigated to develop new vaccines with enhanced efficacy against meningococcal disease.

By genetically adding a factor H binding protein (fHBP, a desirable antigen) into trivalent native OMVs derived from *N. meningitidis* serogroup B strains, the immunogenicity and breadth of the original OMV vaccines were notably improved in mice and infant rhesus macaques ([@B175]). A recent study by Beernink et al. revealed that a native OMV with genetically attenuated endotoxins and overexpressed fHBP has broader meningococcal bactericidal activity in mice ([@B54]). Moreover, this OMV vaccine elicited strong serum bactericidal antibody against gonococci and meningococci. Also, it was found that OMVs displaying a conserved surface polysaccharide antigen poly-N-acetyl-D-glucosamine (PNAG) induced high titers of PNAG-specific IgG antibodies after vaccination in mice ([@B145]). Further, mice immunized with the glycosylated OMVs showed protective immunity against unrelated pathogens, such as *S. aureus* and *Francisella tularensis subspecies Holarctica*. Additionally, extensive studies have been conducted to combat other infectious diseases based on different OMVs derived from *S. typhimurium, A. baumannii, P. gingivalis, T. pallidum, B. burgdorferi, B. pertussis, N. lactamica, H. pylori, P. aeroginosa, V. cholera, Y. pestis*, and *B. melitensis* ([@B30]; [@B153]; [@B172]). For example, a thermostable spray-dried *B. pertussis* OMV vaccine was developed by Kanojia and coworkers, which displayed desirable immune responses and protection against challenge with live *B. pertussis* after pulmonary immunization ([@B72]). Flagellin-deficient *S. typhimurium* OMVs, in combination with outer membrane proteins, induced high cellular immune responses ([@B90]). Also, OMVs enhanced cross-protection on challenge by wild-type virulent *S. choleraesuis* and *S. enteritidis*.

In addition to OMVs derived from Gram-negative bacteria, they can be released by Gram-positive bacteria, such as *S. aureus*, *B. anthracis*, *S. coelicolor*, *L. monocytogenes*, and *B. subtilis* ([@B83]; [@B128]; [@B22]). A recent study showed that OMVs from community-associated MRSA contain cytosolic, surface, and secreted proteins ([@B159]). Moreover, OMVs with genetically engineered, detoxified cytolysins can elicit toxin-neutralizing antibodies in mice, thereby protecting the animals against lethal *S. aureus* sepsis.

Vaccines Based on Other Cell Membrane-Derived Nanoparticles {#s5_6}
-----------------------------------------------------------

Besides vesicles released by different bacteria, nanotechnology has been combined with bacterial mimetic strategies to develop effective vaccine platforms. Recently, a facile approach was established to prepare double-layered membrane vesicles (DMVs) by nitrogen cavitation ([@B157]). DMVs based on a model pathogen *P. aeruginosa* exhibit a whole bacterial membrane and contain a variety of membrane proteins. Consistently, immunization with DMVs effectively promoted the innate and adaptive immune responses in a sepsis model of mice induced by *P. aeruginosa*, thereby improving mouse survival.

On the other hand, *E. coli* OMVs were coated on gold nanoparticles, resulting in hybrid, biomimetic nanovaccines (BM-AuNPs) ([@B50]). After subcutaneous injection of BM-AuNPs in mice, rapid activation and maturation of dendritic cells in the lymph nodes were observed. Of note, BM-AuNPs elicited significantly higher bacteria-specific antibody responses compared to OMVs alone. Furthermore, immunization with BM-AuNPs induced strong Th1- and Th17-biased cell responses against *E. coli* challenge. In another strategy established by the same group ([@B63]), staphylococcal α-hemolysin was entrapped in RBC membrane-coated PLGA nanoparticles. Vaccination with the nanoparticle-detained toxin showed superior protective immunity against toxin-mediated adverse effects. Moreover, multiple virulent toxins secreted by an MRSA strain USA300 were concurrently and naturally presented on a nanosponge derived from RBC membrane-coated PLGA nanoparticles ([@B162]). The formulated multivalent nanotoxoids elicited desirable anti-virulence immunity that can combat live bacterial infections in mice. Notably, both *in vitro* and *in vivo* studies on nanotoxoids revealed good safety profile. Consequently, this biomimetic nanoparticulate platform affords a versatile approach for vaccine development against many infectious diseases.

Concluding Remarks and Future Perspectives {#s6}
==========================================

Biomimetic engineering of nanoparticles is a rapidly developing field, with tremendous advances in the last decade. Taking advantage of the specific delivery and translocation mechanisms adopted by pathogens and mammalian cells, the bioinspired nanoparticles have diverse functions, such as prolonged circulation, enhanced accumulation at infected sites, and reduced off-target effects in healthy tissues. Despite the approval of virosomes and VLPs as novel vaccines, there are still considerable translation barriers for the majority of currently developed biomimetic nanotherapies.

First, biological complexity provides desirable functions to bioinspired nanoplatforms, which simultaneously causes challenges for process control, purification, scaling up production, and reproducible manufacture in the preparation stage. On the basis of the quality-by-design principle, the virtue of simplicity should be followed to facilitate translation studies. Second, regardless of nanoparticles engineered by various biomimetic approaches, their structural features and molecular components are only poorly characterized. Future studies are required to elucidate details regarding the exact components as well as the distribution, arrangement, and orientation of specific biomolecules on the surface of bioinspired nanoparticles, since these parameters are extremely important for their *in vivo* fates and therapeutic efficacies. In this aspect, emerging technologies such as multiplexed protein analysis, proteomics, and imaging mass spectrometry can be used. Establishment of the structure--property correlation will be beneficial for simplifying or optimizing preparation procedures of existing biomimetic nanoparticles. This can also promote the design and development of more effective nanoplatforms. Third, the majority of research works on biomimetic nanoparticles has been focusing on cancer therapy, while only a limited number of studies concern the treatment of infectious diseases, with the exception of virosomes and VLPs. It is worth noting that the biological features of most biomimetic nanoparticles, especially those based on viruses and bacteria, do not guarantee their ideal delivery in cancer treatment. Consequently, the effectiveness and long-term safety issues of newly bioengineered nanotherapies need to be confirmed by comprehensive anti-infective studies. Likewise, mechanistic studies should be conducted to address molecular and cellular events dominating *in vivo* biopharmaceutical and pharmacokinetic profiles of biomimetic nanotherapies currently developed. Finally, it is necessary to further expand the types and functions of biomimetic nanoplatforms, according to new advances in biological and life sciences, in combination with the revolution in nanotechnology. Other cutting-edge technologies, such as computational design, materials genome, and artificial intelligence, can be integrated to discover more effective and translational nanoparticles based on the bioengineering strategies.

Despite the above-mentioned challenges and limitations of bioinspired nanotherapies for anti-infective applications, we may anticipate that the biomimetic strategy-based nanomedicine field will provide novel therapeutics against infectious diseases in the near future, in view of the notable clinical success of bioinspired nanovaccines.
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